Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Do Not Coadminister

Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF)

Ergotamine

Quality of Evidence: Very Low

Summary:

Coadministration is contraindicated due to potential for serious and/or life threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.

Description:

Co-administration is contraindicated due to the potential for serious or life-threatening adverse reactions, such as peripheral vasospasm or ischaemia.
Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.

Coadministration is contraindicated due to potential for increased concentrations of ergotamine and serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Genvoya US Prescribing Information, Gilead Sciences Inc, September 2021.

View all available interactions with Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.